ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Testosterone does not increase cancer risk in men treated for prostate cancer
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 13451" data-attributes="member: 3"><p>Kaplan, A. L., Lenis, A. T., Shah, A., Rajfer, J. and Hu, J. C. (2014), Testosterone Replacement Therapy in Men with Prostate Cancer: A Time-Varying Analysis. Journal of Sexual Medicine. doi: 10.1111/jsm.12768</p><p></p><p>Abstract</p><p>Introduction</p><p>The use of testosterone replacement therapy (TRT) in men with prostate cancer is controversial given concerns of androgen-related cancer progression. Although emerging evidence suggests that TRT may be safe in this setting, no study has investigated dose-related effects.</p><p></p><p>Aim</p><p>We used time-varying analysis to determine whether increasing TRT exposure is associated with worse outcomes.</p><p></p><p>Methods</p><p>Using linked Surveillance, Epidemiology, and End Results-Medicare data, we identified <strong>149,354 men diagnosed with prostate cancer from 1991 to 2007</strong>. Subjects treated with TRT were stratified by duration of treatment. Weighted propensity score methods were used to adjust for differences between groups. A Cox proportional hazards model was constructed to assess the effect of injectable TRT exposure on outcomes.</p><p></p><p>Main Outcome Measure</p><p>Overall mortality (OM), prostate cancer–specific mortality (PCSM), and use of salvage androgen deprivation therapy (ADT).</p><p></p><p>Results</p><p>Men treated with TRT, regardless of duration, did not experience higher OM or PCSM (all hazard ratio<hr /><p> < 1.0, all P ≤ 0.002). We found no difference in use of salvage ADT in the ≤30-day and 31–60 day groups compared with no-TRT (HR 1.23 and 1.05, P = 0.06 and 0.81, respectively), whereas it was lower for men on long-term TRT (HR 0.70, P = 0.04).</p><p></p><p>Conclusions</p><p>TRT following prostate cancer diagnosis and treatment does not increase mortality or the use of salvage ADT. Using time-varying analysis, we demonstrate that longer duration of TRT is not associated with adverse mortality or greater need for ADT.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 13451, member: 3"] Kaplan, A. L., Lenis, A. T., Shah, A., Rajfer, J. and Hu, J. C. (2014), Testosterone Replacement Therapy in Men with Prostate Cancer: A Time-Varying Analysis. Journal of Sexual Medicine. doi: 10.1111/jsm.12768 Abstract Introduction The use of testosterone replacement therapy (TRT) in men with prostate cancer is controversial given concerns of androgen-related cancer progression. Although emerging evidence suggests that TRT may be safe in this setting, no study has investigated dose-related effects. Aim We used time-varying analysis to determine whether increasing TRT exposure is associated with worse outcomes. Methods Using linked Surveillance, Epidemiology, and End Results-Medicare data, we identified [B]149,354 men diagnosed with prostate cancer from 1991 to 2007[/B]. Subjects treated with TRT were stratified by duration of treatment. Weighted propensity score methods were used to adjust for differences between groups. A Cox proportional hazards model was constructed to assess the effect of injectable TRT exposure on outcomes. Main Outcome Measure Overall mortality (OM), prostate cancer–specific mortality (PCSM), and use of salvage androgen deprivation therapy (ADT). Results Men treated with TRT, regardless of duration, did not experience higher OM or PCSM (all hazard ratio [HR] < 1.0, all P ≤ 0.002). We found no difference in use of salvage ADT in the ≤30-day and 31–60 day groups compared with no-TRT (HR 1.23 and 1.05, P = 0.06 and 0.81, respectively), whereas it was lower for men on long-term TRT (HR 0.70, P = 0.04). Conclusions TRT following prostate cancer diagnosis and treatment does not increase mortality or the use of salvage ADT. Using time-varying analysis, we demonstrate that longer duration of TRT is not associated with adverse mortality or greater need for ADT.[/HR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Testosterone does not increase cancer risk in men treated for prostate cancer
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top